SVB Leerink Downgrades Moderna (MRNA) to Underperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Moderna (MRNA) changes point to an 'extended period of underperformance' - SVB Securities
February 24, 2023 10:16 AM ESTModerna (NASDAQ: MRNA) was cut to Underperform from Market Perform by SVB Securities analyst Mani Foroohar on Friday.
Foroohar also lowered the firm's price target on the stock to $93 from $111 following Thursday's reported FY22 results and updated 2023 guidance which "gave a deeper... More
